Cypros Pharmaceutical establishes investment banking relationship with Fahnestock & Co. Inc.CARLSBAD, Calif.--(BUSINESS WIRE)--Dec. 20, 1995--Cypros Pharmaceutical Corp. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CYPR) Wednesday announced that it has retained the investment banking firm Fahnestock & Co. Inc. to advise the company on future product acquisitions and alternatives for financing these acquisitions that would be compatible with the company's business development strategies. The agreement will focus on identifying strategic product acquisitions, licensing opportunities and strategic partnerships as well as structuring the financial transactions to support such activities. Fahnestock is a New York-based, full-service investment banking and brokerage firm that provides a broad range of financial and advisory services advisory services advisory services provided to the public, in their capacity as owners and managers of animals, are an important part of veterinary science. They may be provided by government bureaux, by commercial companies who deal in pharmaceuticals or animals or animal in health care as well as other business sectors. Paul J. Marangos, Ph.D., chairman and chief executive officer, commented: "We look forward to working with a firm of Fahnestock's reputation and ability. Cypros is poised for rapid growth, and we believe this new relationship will facilitate this process." Cypros Pharmaceutical develops and markets acute-care, hospital- based products. The company's three pre-clinical and two clinical development programs focus on cytoprotective drugs designed to reduce ischemia (low blood flow) induced tissue damage in acute care settings. Five Phase II trials are currently in progress, which include three for CPC-111 (coronary artery bypass grafting coronary artery bypass graft n. Abbr. CABG A surgical procedure in which a section of vein or other conduit is grafted between the aorta and a coronary artery below the region of an obstruction in that artery. surgery, congestive heart failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time. and sickle cell anemia sickle cell anemia n. A chronic, usually fatal inherited form of anemia marked by crescent-shaped red blood cells, occurring almost exclusively in Blacks, and characterized by fever, leg ulcers, jaundice, and episodic pain in the joints. crises), and two for CPC-211 (in stroke and head injury patients). The company also markets two intravenous agents (Inulin inulin /in·u·lin/ (in´ul-in) a starch occurring in the rhizome of certain plants, yielding fructose on hydrolysis, and used in tests of renal function. in·u·lin n. and Glofil) used to assess kidney function. CONTACT: Cypros Pharmaceutical Corp., Carlsbad David W. Nassif, 619/929-9500 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion